Optimi Health Plans Phase 3 Trial Of MDMA-Assisted Therapy For PTSD

AMD launched its 6th-gen EPYC 9006 series, codenamed Venice, with up to 256 cores and 512 threads per socket. Built on Zen 6 and TSMC’s 2nm process, these CPUs target agentic AI workloads, including orchestration and data management. The chips support 16 memory channels and PCIe Gen 6, addressing the growing need for efficient AI system integration.

GE Aerospace plans to invest $1 billion in engine repair facilities in Singapore, the UK, Poland, and Hungary, with $300 million for Singapore. The new centers will focus on full engine modules, reducing turnaround time. The investment aims to improve efficiency and cut downtime for older LEAP units through AI inspections and chemical coatings. GE is partnering with Safran and Lufthansa Technik to localize repairs near major airline regions.

Apple has exclusively secured TSMC's 2nm N2 node for its A20 Pro chip, featuring Gate-All-Around transistors. The chip offers 30% better power efficiency and 15% speed boost, enabling advanced AI. TSMC's 2nm technology uses a GAA nanosheet design, reducing electrical leakage. The A20 Pro will be in the iPhone 18 Pro, with high production costs estimated at USD 30,000 per wafer.

Egypt received the first five of 12 Boeing CH-47F Chinook helicopters, part of a $426M deal. The F-model features digital cockpits and stronger airframes, replacing older CH-47D models. Deliveries will continue through 2026, with Egypt upgrading its fleet and infrastructure to accommodate the new helicopters.

Tesla has reopened reservations for its next-generation Roadster, requiring a $50,000 deposit ahead of its October 1 unveiling. The deposit includes a $5,000 credit card payment and a $45,000 wire transfer. The first round of deposits, taken in 2017, has not yet resulted in any deliveries. Tesla promises to reveal pricing, specs, and production targets at the event, with Elon Musk teasing advanced features. Prediction markets show low confidence in the Roadster's delivery by 2026.

Definium Therapeutics (DFTX) reported positive Phase 3 trial results for its LSD-based anxiety drug, DT120. The trial showed a 5.1-point improvement over placebo, similar to its previous trial. Psychedelic stocks often move together, and Definium's success could impact the broader sector. Hedge fund holdings of DFTX have increased, indicating growing institutional confidence.